---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-075260"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:28:33.861176+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coya reports positive proof-of-concept data for COYA 302 in ALS; Treg function up, biomarkers down, ALSFRS stable

## Summary
- Treatment with IL-2/CTLA4-Ig (COYA 302) over 48 weeks significantly increased Treg suppressive function and Treg numbers in 4 ALS patients.
- Biomarkers of oxidative stress (4-HNE, ox-LDL) were reduced; mean ALSFRS-R scores not statistically different from baseline, suggesting disease stabilization.
- Adverse events limited to mild injection site reactions; no deaths or serious AEs; all 4 patients completed the study.
- Study is open-label, single-arm, proof-of-concept; data supports further development of COYA 302 for ALS.

## SEC filing metadata
- accession: 0001193125-23-075260
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312523075260/0001193125-23-075260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312523075260/d464304d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-075260
- JSON: https://secwatch.observer/filing/0001193125-23-075260.json
- Plain text: https://secwatch.observer/filing/0001193125-23-075260.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.